| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 132 | / | 2013 | ||||||||
| Date of issue: | 2013-10-17 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Current report 132 buy back 17102013 | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| SOPHARMA AD (the “Company") hereby informs that from 10 October 2013 up to and including 16 October 2013 the Company bought 7 650 own shares representing 0.0058% of the share capital of the Company, to the total value of 24 998.10 BGN on the Bulgarian Stock Exchange. The average price per share was 3.27 BGN. The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 297 645, representing 4.01% of the share capital of the Company. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Current report 132 buy back 17102013.doc | Current report 132 buy back 17102013 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2013-10-17 | Ognian Donev | Executive director | |||
